XNASVVOS
Market cap25mUSD
Jan 08, Last price
4.37USD
1D
0.37%
1Q
89.18%
IPO
-43.90%
Name
Vivos Therapeutics Inc
Chart & Performance
P/E
—
P/S
1.86
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.43%
Rev. gr., 5y
29.48%
Revenues
14m
-13.87%
Net income
-14m
L-40.05%
CFO
-12m
L-39.01%
Earnings
Mar 26, 2025
Profile
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 13,801 -13.87% | 16,024 -5.10% | ||||
Cost of revenue | 30,576 | 40,586 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (16,775) | (24,562) | ||||
NOPBT Margin | ||||||
Operating Taxes | (1,186) | |||||
Tax Rate | ||||||
NOPAT | (16,775) | (23,376) | ||||
Net income | (13,583) -40.05% | (22,659) 11.66% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 12,000 | |||||
BB yield | -79.11% | |||||
| Debt | ||||||
Debt current | 948 | 419 | ||||
Long-term debt | 3,516 | 4,407 | ||||
Deferred revenue | 289 | 112 | ||||
Other long-term liabilities | 1,220 | 112 | ||||
Net debt | 2,821 | 1,307 | ||||
| Cash flow | ||||||
Cash from operating activities | (11,946) | (19,587) | ||||
CAPEX | (853) | (924) | ||||
Cash from investing activities | (853) | (924) | ||||
Cash from financing activities | 10,923 | |||||
FCF | (13,787) | (24,358) | ||||
| Balance | ||||||
Cash | 1,643 | 3,519 | ||||
Long term investments | ||||||
Excess cash | 953 | 2,718 | ||||
Stockholders' equity | (93,051) | (79,466) | ||||
Invested Capital | 97,440 | 86,904 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 1,219 | 920 | ||||
Price | 12.44 2,994.53% | 0.40 -82.13% | ||||
Market cap | 15,169 3,999.37% | 370 -80.64% | ||||
EV | 17,990 | 1,677 | ||||
EBITDA | (16,154) | (23,893) | ||||
EV/EBITDA | ||||||
Interest | 1,186 | |||||
Interest/NOPBT | ||||||